In our patient imiquimod 3.75% cream showed an acceptable tolerability profile with the advantage of being self-applied by the patient, showing an efficacy not only at the level of actinic keratosis and NMSCs, but also in case solar lentigo (SL). Further studies are necessary to validate the use of imiquimod also for benign skin lesions, associated with chronic skin photodamage.
Efficacy of imiquimod 3.75% cream for the treatment of solar lentigo / Cantisani, Carmen; Cantoresi, Franca; Mercuri, Santo Raffaele; Binic, Ivana; Golubovic, Milena; Marino, Raffaella; Paolino, Giovanni. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - (2020), pp. 1-2. [10.1111/dth.13256]
Efficacy of imiquimod 3.75% cream for the treatment of solar lentigo
Cantisani, Carmen
;Cantoresi, Franca;Paolino, Giovanni
Ultimo
2020
Abstract
In our patient imiquimod 3.75% cream showed an acceptable tolerability profile with the advantage of being self-applied by the patient, showing an efficacy not only at the level of actinic keratosis and NMSCs, but also in case solar lentigo (SL). Further studies are necessary to validate the use of imiquimod also for benign skin lesions, associated with chronic skin photodamage.| File | Dimensione | Formato | |
|---|---|---|---|
|
Cantisani_Efficacy-of-imiquimod_2020.pdf
solo gestori archivio
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
444.72 kB
Formato
Adobe PDF
|
444.72 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
